Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,301
datasets available to search
ShareScore release 0.9.0
Dataset results
1,301 results for “retrospective study”
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL).
ClinicalTrials.gov study NCT00301314. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Medical Thoracoscopy for Diagnosing Unexplained Pleural Effusion: a National Multicenter Retrospective Study
ClinicalTrials.gov study NCT06275178. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study
ClinicalTrials.gov study NCT06851845. IPD Sharing: NO. Countries: 0. Publications: 0.
A Retrospective Study of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis
ClinicalTrials.gov study NCT06275295. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Indocyanine Green Fluorescence-guided Sentinel Node Biopsy in Breast Cancer Within a North African Population: a Retrospective Study
ClinicalTrials.gov study NCT04879680. IPD Sharing: NO. Countries: 0. Publications: 0.
Impact of Early Cardiac Surgery in Severe Left Endocarditis With Neurological Complications: a Retrospective Study
ClinicalTrials.gov study NCT04387513. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study
ClinicalTrials.gov study NCT06150222. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
A Non-interventional Retrospective Study on Overall Survival in Completely Resected Chinese NSCLC Patients With Adenocarcinoma Histology- ICAN Extension Study
ClinicalTrials.gov study NCT03658928. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Retrospective Study of the Effects of Molecular Diagnostics on Wound Care Outcomes
ClinicalTrials.gov study NCT01089673. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Comparison of Clinical Effect Between Endoscopic and Microscopic Ear Surgery of Cholesteatoma: A Multicenter Retrospective Observational Study
ClinicalTrials.gov study NCT05182268. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer
ClinicalTrials.gov study NCT05934461. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Relationship of Point-of-care Coagulation Assays with Clinical Outcomes in Cardiac Surgery: a Retrospective Cohort Study
ClinicalTrials.gov study NCT06882759. IPD Sharing: NO. Countries: 0. Publications: 0.
Retrospective Study of Patients with Acute Presentation for Asthma to an Emergency Department in UK (RAPAE)
ClinicalTrials.gov study NCT06360185. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Long-term stability of dental arch widths after extraction and non-extraction orthodontic treatment: a retrospective cohort study
<p>Dataset for all analyses. Initially, access will be granted to the editor and the peer reviewers. After acceptance, unrestricted access will be granted to everyone.</p>
Dataset related to article "Real-life Effectiveness and Safety of Risankizumab in Moderateto- severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study"
<p>This record contains data related to article "Real-life Effectiveness and Safety of Risankizumab in Moderateto- severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study"</p> <p>Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in monotherapy up to week 40 in a “real-life” setting. At week 40, 98.7%, 85.7% and 62.3% of patients achieved a Psoriasis Area and Severity Index (PASI) reduction ≥ 75% (PASI 75), PASI 90 and PASI 100, respectively. Patients who had not responded to 2 or more previous biologic treatments were significantly less likely to achieve PASI 75/90 at week 16 and PASI 90/100 at week 40 compared<br> with those who had been previously treated with<br> only 1 biologic, and compared with those treated with risankizumab as a first-line biologic. Increasing body mass index decreased the chances of reaching PASI 90 at week 40. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment. These data suggest that the efficacy of risankizumab for plaque psoriasis in “real-life” clinical practice could differ from pivotal clinical trials data.</p>
Dataset related to article "Gamma Knife Radiosurgery for the Treatment of Trigeminal Neuralgia in Patients with Multiple Sclerosis: A Single-Center Retrospective Study and Literature Review" "
<p>This record contains raw data related to article “Gamma Knife Radiosurgery for the Treatment of Trigeminal Neuralgia in Patients with Multiple Sclerosis: A Single-Center Retrospective Study and Literature Review"</p> <p><strong>Objective: </strong> Trigeminal neuralgia (TN) in patients with multiple sclerosis (MS) is a challenging condition to manage that is treated with Gamma Knife radiosurgery (GKRS). The aim of this report is to assess the safety, efficacy, and durability of GKRS for the treatment of TN in patients with MS. Our findings are compared with those of the existing literature and discussed.</p> <p><strong>Methods: </strong> We retrospectively reviewed all patients at our institution who underwent GKRS for the treatment of TN secondary to MS and had 1 or more years of follow-up. Preoperative and postoperative pain intensities and facial numbness were evaluated with the Barrow Neurological Institute scores. Durability of successful pain relief was statistically evaluated with Kaplan-Meier analysis. The prognostic role of perioperative factors was investigated and analyzed using Cox proportional hazards regression.</p> <p><strong>Results: </strong> There were 29 patients with MS-TN who underwent GKRS at our institution. Two patients underwent bilateral treatment. Four patients underwent repeat GKRS for pain recurrence. The median period of follow-up assessment was 33 months. Rates of reasonable pain reduction at 1, 3, and 5 years were 70%, 57%, and 57% respectively. All patients who underwent repeat GKRS had durable pain reduction. No prognostic factor for successful pain reduction was found.</p> <p><strong>Conclusions: </strong> Our study shows that GKRS for the treatment of TN secondary to MS is a safe and effective procedure in controlling pain in the short term but often fails to provide long-term pain control. GKRS can be safely repeated to prolong the time of pain reduction.</p>
Dataset related to article "Cognitive and behavioral associated changes in manifest Huntington disease A retrospective cross-sectional study"
<p>.xls dataset containing clinical and neuropsychological data of HD patients included in the study described at title by Fondazione Besta</p>
Per- and polyfluoroalkyl substances (PFASs) exposure in melanoma patients: a retrospective study on prognosis and histological features
<p>Per- and polyfluoroalkyl substances (PFASs) are endocrine disrupting chemicals and previous studies showed that they could be associated with altered vitamin D levels. Since 1965, a massive environmental contamination by PFASs has occurred in North-eastern Italy. This study compared histopathology and prognosis between melanoma patients exposed (n=194) and unexposed (n=488) to PFAS. All patients were diagnosed and/or treated for melanoma at the Veneto Oncological Institute and the University Hospital of Padua (Italy) in 1998-2014. Patients were stratified according to the area of residency and the classification provided by the regional administration. Presence of mitoses was found in 70.5% of exposed patients and 58.7% of unexposed patients (p=0.005). Median follow-up was 90 months (IQR 59-136). 5-year overall survival was 83.7% in exposed patients and 88.0% in unexposed patients (p=0.20); 5-year disease-specific survival was 88.0% in exposed patients and 90.9% in unexposed patients (p=0.50); 5-year disease-free survival was 83.8% in exposed patients and 87.3% in unexposed patients (p=0.20). Our findings suggested that exposure to PFAS was associated with higher level of mitosis in melanoma patients, which may be related to the vitamin D deficiency induced by PFAS. Further studies are required to investigate this relationship and all effects of PFAS on prognosis.</p>
Prognostic Factors in Merkel Cell Carcinoma:A Retrospective Single-Center Study in 90 Patients
<p>Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04⁻8.16) and disease-specific (HR 4.62, 95% CI 1.31⁻16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06⁻4.36) and recurrence-free (HR 3.08, 95% CI 1.44⁻6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival</p>
Clinical Dataset for Risk Factors for Overall Survival in Hospitalized Adults Receiving Total Parenteral Nutrition: A Retrospective Cohort Study at a Social Security Hospital in Peru: January 2022 – June 2023
<p>This Excel dataset contains de-identified clinical data collected over a two-year period, aimed at evaluating risk factors associated with 90-day mortality in hospitalized patients receiving total parenteral nutrition (TPN). The dataset includes variables such as age, sex, clinical diagnosis, comorbidities, days in the ICU, days receiving TPN, laboratory values (lymphocytes, platelets, TGP), and the presence of acute kidney injury (AKI) or chronic kidney disease (CKD).</p> <p>The data is structured in rows, with each row representing an individual patient, and columns corresponding to the various clinical and laboratory parameters. It was used to perform survival analysis using Cox proportional hazards models and other statistical techniques. Sensitive information has been removed to ensure patient confidentiality.</p> <p>Access to the dataset is restricted, and permission must be requested for its use in further research.</p> <p><strong>File format:</strong> Excel (.xlsx)<br><strong>Keywords:</strong> Total Parenteral Nutrition, 90-Day Mortality, Risk Factors, Clinical Dataset, Cox Regression</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.